Literature DB >> 29313098

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy.

Seiichi Kato1, Makoto Kawase2, Daiki Kato2, Takashi Ishida2, Masahiro Uno2, Yoshinori Fujimoto2, Takako Masue3, Naruyasu Masue3, Takashi Deguchi4.   

Abstract

The aim of this study was to conduct a cross-sectional survey of investigations related to the bone mineral density (BMD) of both non-metastatic prostate cancer (NMPC) patients who have not yet received androgen deprivation therapy (ADT) and patients receiving prolonged ADT in Japan. Japanese male patients with NMPC who received continuous ADT or who were planning to receive ADT were enrolled in this study. Lumbar spine and femoral neck BMD was measured using dual-energy X-ray absorptiometry (DEXA). To assess patient characteristics, we searched medical records and questionnaires to determine whether they had any factors that could possibly affect BMD. A total of 230 patients with a mean age of 76.6 ± 6.4 years were evaluated. Of these, 151 (65.7%) were receiving ADT, and 79 (34.4%) had not yet received ADT. The mean duration of ADT was 37.4 ± 30.7 months. DEXA showed that as the duration of ADT increased, lumbar spine and femoral neck BMD decreased gradually (p = 0.0005 and p = 0.0014, respectively). Stepwise regression analyses revealed that the duration of ADT was a significant variable of both lumbar spine and femoral neck BMD. Moreover, as the duration of ADT increased, the prevalence of osteoporosis increased statistically (p = 0.0002). This study showed that ADT negatively affected lumbar spine and femoral neck BMD. It also showed a progressive increase in the prevalence of osteoporosis in Japanese NMPC patients with ADT.

Entities:  

Keywords:  Asian Continental Ancestry Group; Bone density; Gonadotropin-releasing hormone; Osteoporosis; Prostatic neoplasms

Mesh:

Substances:

Year:  2018        PMID: 29313098     DOI: 10.1007/s00774-017-0897-5

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  2 in total

1.  Assessment of bone health in patients with prostate cancer using cancer staging computed tomography.

Authors:  Mototaka Sato; Masafumi Kashii; Atsuki Matsukawa; Ryoya Mizuno; Mai Akiyama; Takashi Kamatani; Satoshi Kamido; Norichika Ueda; Jiro Nakayama; Norihide Tei; Hideki Yoshikawa; Osamu Miyake
Journal:  J Bone Miner Metab       Date:  2022-05-12       Impact factor: 2.976

2.  Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.

Authors:  Daisuke Watanabe; Takahiro Kimura; Ken Watanabe; Hiromitsu Takano; Yuko Uehara; Tadaaki Minowa; Akemi Yamashita; Seiichiro Yoshikawa; Akio Mizushima
Journal:  BMC Cancer       Date:  2021-04-17       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.